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OBJECTIVE: This study aimed to analyse whether age, metastasis, extrathyroidal invasion and size
(AMES) risk definition is valuable for Japanese patients with differentiated thyroid carcinoma (DTC).
METHODS: Two hundred and fifteen Japanese DTC patients (43 men, 172 women; mean age, 51.0 years;
mean follow-up, 102 months) treated surgically at our institutions between 1981 and 2001 were retro-
spectively analysed. Clinicopathological features were compared between high-risk and low-risk patients
by AMES criteria. Various risk factors were also evaluated for each group of patients.
RESULTS: There were 57 high-risk and 158 low-risk patients. Recurrence and mortality rates were 43.9% and
24.6% in high-risk patients and 7.6% and 0.6% in low-risk patients, respectively (p < 0.0001). Disease-specific
survival rates at 5, 10 and 15 years were 84.3%, 74.0% and 63.5% in high-risk patients and 100%, 100% and
98.3% in low-risk patients, respectively (p < 0.0001). Univariate analysis revealed that curative resection, local
recurrence and distant metastasis were risk factors for mortality in the high-risk group. Multivariate analysis
revealed that curative resection (hazard ratio [HR], 4.68; 95% confidence interval [CI], 1.23–17.83; p = 0.024)
and distant metastasis (HR, 4.79; 95% CI, 1.24–18.40; p = 0.023) were significantly related to mortality in
high-risk patients.
CONCLUSION: AMES can identify high-risk and low-risk Japanese patients. Distant metastasis and
curative resection are prognostic factors for disease-specific death. [Asian J Surg 2007;30(2):102–7]
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Introduction
The age, metastasis, extrathyroidal invasion and size (AMES)
criteria have been used to identify high-risk and low-risk
patients with differentiated thyroid carcinoma (DTC).1–10
The rates of recurrence are 28% in high-risk patients and
14–46% in low-risk patients, and those for mortality are
4–8% and 1–2.4%, respectively.1,2,4–6 Long-term survival rates
range from 47% to 94% in high-risk patients, as compared
with 96–100% in low-risk patients.6,9,10 Various prognostic
factors have been proposed for patients with DTC.2–7, 9–18
The extent of thyroidectomy and lymph node dissection
(LND) has been the major source of controversy. Other
adjuvant therapies after surgery such as radioactive iodine
(RI) therapy, extra beam radiation therapy (EBRT), and
thyroid-stimulating hormone (TSH) suppression also
remains controversial.
The aim of this study was to analyse whether AMES risk
definition is valuable for Japanese DTC patients. Moreover,
whether high-risk patients have prognostic factors was
investigated. In Japan, RI ablation has been less frequently
performed in clinical practice because RI treatment is
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restricted and can only be performed at a limited number of
hospitals. Therefore, total or near total thyroidectomy fol-
lowed by RI ablation is infrequent. We describe our experi-
ence with the AMES criteria for risk assessment in patients
who underwent surgery for DTC and evaluated the prog-
nostic factors related to recurrence or disease mortality.
Patients and methods
Clinical outcomes were retrospectively evaluated in 
215 patients with DTC (43 men, 172 women; mean age,
51.0 years; mean follow-up, 102 months) treated surgically
at Yokohama City University Hospital and Medical Center
between 1981 and 2001. Patients were divided into high-risk
and low-risk groups according to the AMES risk criteria,1
as shown in Table 1, and the clinicopathological features
were compared between the two groups. AMES risk defi-
nition has particularly been used in our clinical practice
because the criteria are extremely straightforward. The
clinicopathological features compared were age, gender,
primary tumour size, pathology, extent of surgery, node
dissection, lymph node metastasis (LNM), TSH suppres-
sion therapy, radiotherapies (RI and EBRT), recurrence,
disease mortality and survival rates, as shown in Table 2.
These features were also compared between patients with
and without recurrence or disease-specific death accord-
ing to risk group. In addition, prognostic factors for dis-
ease mortality in the high-risk group were evaluated in
univariate and multivariate analyses. Curative resection
in this study was defined as complete removal of tumour
both macroscopically and microscopically regardless of
the extent of surgery. Patients who underwent less total
thyroidectomy were included in the curative resection
group when there was no evidence of residual tumour after
surgery. Node dissection in this study was therapeutic or
prophylactic modified neck dissection (MND). Ipsilateral
MND was node dissection in both central (pretracheal and
paratracheal) compartment and ipsilateral lateral compart-
ment. The frequency of LNM was defined as the number of
patients with LNM including pathologically identified
positive node divided by total number of patients.
Statistical analysis
Statistical analysis was performed with the use of Student’s
t test or the Mann–Whitney test, as appropriate. Frequencies
were compared with the χ2 test and Fisher’s exact proba-
bility test. Disease-specific survival curves were assessed
with the Kaplan–Meier method and compared with the use
of the log-rank test. Univariate and multivariate analyses
were used to evaluate the impact of prognostic factors on
outcome. Multivariate regression analysis was performed
with the use of a Cox proportional-hazards model on fac-
tors found to be significant in univariate analysis. Hazard
ratios (HR) (95% confidence interval [CI]) were calculated
for significant prognostic factors. Differences were con-
sidered statistically significant when p values were < 0.05.
Statistical analyses were performed with StatView-J, version
5.0 (SAS Institute Inc., Cary, NC, USA).
Results
Patient characteristics and clinicopathological data are
summarized in Table 2. There were 57 (26.5%) high-risk
and 158 (73.5%) low-risk patients. The high-risk group had
53 papillary thyroid carcinomas (PTCs) and four follicular
Table 1. High-risk and low-risk patients according to the age,
metastasis, extrathyroidal invasion and size (AMES) risk criteria
High-risk group (n = 57)
Younger patients (men ≤ 40, women ≤ 50) 2 (3.5%)
PTC with distant metastasis 2
Older patients (men > 40, women > 50) 55 (96.5%)
PTC with 
(a) Extrathyroid invasion 42
(b) Distant metastasis 2
(c) Primary tumour (≥ 5 cm)
(a) and (b) 4
(a) and (c) 2
(a), (b) and (c) 1
FTC with 
(a) Wide invasion 2
(b) Distant metastasis 
(c) Primary tumour (≥ 5 cm)
(a) and (b) 1
(a) and (c) 1
Low-risk group (n = 158)
Younger patients (men ≤ 40, women ≤ 50) 81 (51.3%)
without distant metastasis
PTC 74
FTC 7
Older patients (men > 40, women > 50) 77 (48.7%)
primary tumour (< 5 cm) without 
distant metastasis
PTC without extrathyroid invasion 72
FTC with minimal invasion 5
PTC=papillary thyroid carcinoma; FTC= follicular thyroid carcinoma.
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thyroid carcinomas (FTCs), and the low-risk group had
146 PTCs and 12 FTCs. Subtotal or total thyroidectomy
was performed in 50.9% of the high-risk patients and
36.7% of the low-risk patients. Systematic LND was done
in 47 (82.5%) high-risk patients and 93 (58.9%) low-risk
patients. The level of TSH was sufficient for suppression
therapy in 55 (96.5%) high-risk patients and 89 (56.3%) low-
risk patients. RI therapy and EBRT were performed in five
(8.8%) and three (5.3%) high-risk patients and in two (1.3%)
and one (0.6%) low-risk patients, respectively.
Recurrence occurred in 43.9% of high-risk patients
and 7.6% of low-risk patients (p < 0.0001). Mortality rates
were 24.6% (14/57) in the high-risk group and 0.6% (1/158)
in the low-risk group (p < 0.0001). Kaplan–Meier curves of
disease-specific survival significantly differed between the
two groups (p < 0.0001), as shown in Figure A. Survival
rates at 5, 10 and 15 years were 84.3%, 74.0% and 63.5% 
in the high-risk group and 100%, 100% and 98.3% in the
low-risk group, respectively.
Table 3 compares the clinicopathological features of
patients with and without recurrence or disease-specific
death in high-risk patients. Gender and curative resection
were significantly related to recurrence. Subtotal or total
thyroidectomy was performed more in a higher proportion
of high-risk patients with recurrence than in those without
recurrence. Pathology and TSH suppression therapy had no
influence on clinical outcome. Radiotherapy could not be
evaluated concerning the relation to recurrence or disease
mortality in high-risk patients because only a small number
of patients received RI therapy, EBRT, or both.
As shown in Tables 3 and 4, and Figures B, C and D,
univariate analysis and Kaplan–Meier survival curves
Table 2. Patient characteristics and clinicopathological data
High-risk group (n = 57) Low-risk group (n = 158) p
Mean age (yr) 59.3 48.0 p < 0.0001 
Gender (M:F) 12:45 31:127 NS
Mean size (cm) 3.9 2.2 p < 0.0001
Pathology 
Papillary 53 (93.0%) 146 (92.4%) NS 
Follicular 4 (7.0%) 12 (7.6%) NS 
Extent of surgery 
Lobectomy 28 (49.1%) 100 (63.3%) NS
Subtotal/total 29 (50.9%) 58 (36.7%) NS
Node dissection 47 (82.5%) 93 (58.9%) p = 0.0012
LNM 36/47 (76.6%) 67/93 (72.0%) NS
TSH suppression 55 (96.5%) 89 (56.3%) p < 0.0001
Radiotherapy 8 (14.0%) 3 (1.9%) p = 0.0014
RI 5 (8.8%) 2 (1.3%) p = 0.0152
EBRT 3 (5.3%) 1 (0.6%) NS
Recurrence 25 (43.9%) 12 (7.6%) p < 0.0001
Local 8 6
Distant 9 4
Local + distant 8 2
Mortality rate 14 (24.6%) 1 (0.6%) p < 0.0001
Survival rates
5 yr 84.3% 100.0% p < 0.0001
10 yr 74.0% 100.0%
15 yr 63.5% 98.3%
LNM was analysed in 47 (82.5%) high-risk and 93 (58.9%) low-risk patients who underwent systematic LND (ipsilateral or bilateral MND).
NS=not significant; LNM= lymph node metastasis; TSH= thyroid-stimulating hormone; RI= radioiodine; EBRT=extra beam radiation therapy.
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showed that curative resection, local recurrence, and distant
metastasis were significantly related to disease mortality
in high-risk patients. Multivariate analysis showed that
curative resection (HR, 4.68; 95% CI, 1.23–17.83; p = 0.024)
and distant metastasis (HR, 4.79; 95% CI, 1.24–18.40;
p = 0.023) had statistical significance.
Discussion
AMES risk definition has identified high-risk and low-risk
patients with DTC.1–10 Our study also revealed significant
differences between the two groups. In previous studies
(including our results), rates of recurrence and mortality
have ranged from 28% to 44% and 14–46% in high-risk
patients, as compared with 4–8% and 0.6–2.4% in low-risk
patients.1,2,4–6
Various risk factors have been studied in DTC
patients.2–7,9–18 Age and tumour size had no impact on
outcome in our high-risk patients. Male gender was statisti-
cally associated with recurrence. Node dissection and TSH
suppression were more commonly performed in high-risk
patients than in low-risk patients; however, we could not
find any significant impact on the clinical results.
Curative resection and distant metastasis were signifi-
cantly related to disease-specific death in high-risk patients,
consistent with the results of previous investigations.2
In this study, curative resection was less frequently per-
formed in high-risk patients who developed recurrence or
death from disease than in those who did not (72.0% vs.
96.9% for recurrence, 57.1% vs. 95.3% for death). Multivariate
analysis revealed that curative resection (HR, 4.68; 95% CI,
1.23–17.83; p = 0.024) and distant metastasis (HR, 4.79;
95% CI, 1.24–18.40; p = 0.023) were risk factors for disease
mortality in high-risk patients. Thus, high-risk patients
likely to have poor prognosis can be predicted by risk 
factor analysis and then assigned appropriate treatment
Table 4. Risk factor analysis of disease-specific death in AMES high-risk patients (n = 57)
Survival curves (Kaplan–Meier) Multivariate analysis
p HR 95% CI p
Curative resection < 0.0001 4.68 1.23–17.83 0.024
Local recurrence = 0.0110 2.2 0.70–6.92 0.178
Distant metastasis < 0.0001 4.79 1.24–18.40 0.023
HR = hazard ratio; CI = confidence interval.
Table 3. Univariate risk factor analysis of recurrence or disease-specific death in AMES high-risk patients (n = 57)
Recurrence Disease-specific death
(+) (n = 25) (–) (n = 32) p (+) (n = 14) (–) (n = 43) p
Mean age (yr) 61.0 57.8 NS 62.9 58.0 NS
Gender (M:F) 9:16 3:29 0.014 3:11 9:34 NS
Mean size (cm) 4.2 3.5 NS 4.3 3.7 NS
Extent of surgery 0.033 NS
Lobectomy 8 (32.0%) 20 (62.5%) 5 (35.7%) 23 (53.5%)
Subtotal/total 17 (68.0%) 12 (37.5%) 9 (64.3%) 20 (46.5%)
LNM 17/19 (89.5%) 19/28 (67.9%) NS 9/10 (90.0%) 27/37 (73.0%) NS
Curative resection 18 (72.0%) 31 (96.9%) < 0.001 8 (57.1%) 41 (95.3%) 0.0017
Local recurrence NA 8 (57.1%) 8 (18.6%) 0.0143
Distant metastasis NA 10 (71.4%) 7 (16.3%) 0.0003
LNM = lymph node metastasis; NS = not significant.
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strategies. In particular, curative resection is a more impor-
tant risk factor that can be evaluated at the time of surgery.
Local recurrence and distant metastasis are risk factors
that have usually been found in the follow-up period.
Therefore, complete resection is considered essential to
prevent adverse prognosis when primary cancers present
with extrathyroidal invasion to adjacent neck structures.
To the contrary, we could not find any risk factors for
low-risk patients.
There has been an unusual dilemma pertaining to RI
treatment. Radiotherapy (RI therapy, EBRT or both) con-
tribute to improved survival in patients who undergo
incomplete resection.2 RI therapy for distant metastasis is
also considered to decrease disease mortality.2,13,17,18 We
reviewed our experience without RI ablation as adjuvant
therapy because of the different background to use radioio-
dine. In Japan, RI treatment is restricted and can be per-
formed at a limited number of hospitals only. RI ablation
is therefore not routinely performed after initial surgery.
Japanese patients usually receive RI therapy when distant
metastasis is visually detected on chest X-ray or computed
tomography. In this study, only 8.8% of high-risk patients
received therapeutic RI treatment. We therefore cannot
delineate the effect of RI treatment on our clinical out-
comes. Our results showed relatively high recurrence and
mortality rates but this may be due to selection bias in
patients referred to us because our institution has con-
tributed as a tertiary teaching hospital. Moreover, poor
clinical outcomes are likely to be attributed to the less fre-
quent application of RI treatment. We consider that more
frequent use of RI may improve the outcome in our high-
risk patients. This issue needs to be considered in our
present and future practice.
In conclusion, AMES risk definition can distinguish
high-risk patients from low-risk patients. Our findings
suggest that the curability of primary tumour resection
and distant metastasis are significantly associated with
disease mortality. We conclude that AMES is valuable for
Japanese patients with DTC and both curative resection
and distant metastasis are prognostic factors for death
from disease in AMES high-risk patients.
References
1. Cady B, Rossi R. An expanded view of risk-group definition in
differentiated thyroid carcinoma. Surgery 1988;104:947–53.
Su
rv
iv
al
 r
at
e 
(%
)
Low-risk group (n=158)
High-risk group (n = 57)
p < 0.0001
0
0
20
40
60
80
100
5 10 15 20
Time (yr)
A
Local recurrence
0
20
40
60
80
100
p = 0.0110
Yes (n = 16)
No (n = 41)
Su
rv
iv
al
 r
at
e 
(%
)
0 5 10 15 20
Time (yr)
C
0
20
40
60
80
100
p < 0.0001 
Distant metastasis
Su
rv
iv
al
 r
at
e 
(%
)
Yes (n = 17)
No (n = 40)
Time (yr)
D
0 5 10 15 20
0
20
40
60
80
100
p < 0.0001
Curative resection
Yes (n = 49)
No (n = 8)
Su
rv
iv
al
 r
at
e 
(%
)
Time (yr)
B
0 5 10 15 20
Figure. (A) Kaplan–Meier curves of disease-specific survival for AMES high-risk (n = 57) and low-risk (n = 158) patients. (B–D) Kaplan–
Meier curves of disease-specific survival for AMES high-risk patients (n = 57) according to three prognostic factors (curative resec-
tion, local recurrence and distant metastasis) indicated in univariate analysis.
■ CLINICAL OUTCOME BY AMES IN DTC ■
ASIAN JOURNAL OF SURGERY VOL 30 • NO 2 • APRIL 2007 107
2. Lo CY, Chan WF, Lam KY, Wan KY. Optimizing the treatment of
AMES high-risk papillary thyroid carcinoma. World J Surg 2004;
28:1103–9.
3. Haigh PI, Urbach DR, Rotstein LE. AMES prognostic index and
extent of thyroidectomy for well-differentiated thyroid cancer in
the United States. Surgery 2004;136:609–16.
4. Voutilainen PE, Siironen P, Franssila KO, et al. AMES, MACIS and
TNM prognostic classifications in papillary thyroid carcinoma.
Anticancer Res 2003;23:4283–8.
5. Hay ID, Grant CS, Bergstralh EJ, et al. Unilateral total lobectomy:
is it sufficient surgical treatment for patients with AMES low-risk
papillary thyroid carcinoma? Surgery 1998;124:958–64.
6. Sanders LE, Cady B. Differentiated thyroid cancer: reexamina-
tion of risk groups and outcome of treatment. Arch Surg
1998;133:419–25.
7. Van Nguyen K, Dilawari RA. Predictive value of AMES scoring
system in selection of extent of surgery in well differentiated 
carcinoma of thyroid. Am Surg 1995;61:151–5.
8. Pasieka JL, Zedenius J, Auer G, et al. Addition of nuclear DNA
content to the AMES risk-group classification for papillary thyroid
cancer. Surgery 1992;112:1154–9.
9. Orsenigo E, Beretta E, Fiacco E, et al. Management of papillary
microcarcinoma of the thyroid gland. Eur J Surg Oncol 2004;
30:1104–6.
10. Marchesi M, Biffoni M, Biancari F, et al. Predictors of outcome
for patients with differentiated and aggressive thyroid carcinoma.
Eur J Surg Suppl 2003;588:46–50.
11. Pacini F, Elisei R, Capezzone M, et al. Contralateral papillary
thyroid cancer is frequent at completion thyroidectomy with 
no difference in low- and high-risk patients. Thyroid 2001;11:
877–81.
12. Wanebo H, Coburn M, Teates D, Cole B. Total thyroidectomy
does not enhance disease control or survival even in high-risk
patients with differentiated thyroid cancer. Ann Surg 1998;227:
912–21.
13. Loh KC, Greenspan FS, Gee L, et al. Pathological tumor-node-
metastasis (pTNM) staging for papillary and follicular thyroid
carcinomas: a retrospective analysis of 700 patients. J Clin
Endocrinol Meta 1997;82:3553–62.
14. Shaha AR, Shah JP, Loree TR. Low-risk differentiated thyroid
cancer: the need for selective treatment. Ann Surg Oncol 1997;4:
328–33.
15. Balazs G, Gyory F, Lukacs G, Szakall S. Long-term follow-up of
node-positive papillary thyroid carcinomas. Langenbecks Arch Surg
1998;383:180–2.
16. Musacchio MJ, Kim AW, Vijungco JD, Prinz RA. Greater local
recurrence occurs with “berry picking” than neck dissection in
thyroid cancer. Am Surg 2003;69:191–6.
17. Conrad MF, Pandurangi KK, Parikshak M, et al. Postoperative
surveillance of differentiated thyroid carcinoma: a selective
approach. Am Surg 2003;69:244–50.
18. Chow SM, Law SC, Chan JK, et al. Papillary microcarcinoma of
the thyroid: prognostic significance of lymph node metastasis
and multifocality. Cancer 2003;98:31–40.
